Innate Pharma Partners with Sobi to Advance Lacutamab into Phase 3 for Rare T-Cell Lymphoma

Innate Pharma teams up with Sobi to launch TELLOMAK-3 Phase 3 trial of lacutamab for rare T-cell lymphoma, with $75M upfront and new CMO.